18488874|t|HT update: spotlight on estradiol/norethindrone acetate combination therapy.
18488874|a|Abstract: The goal ofpostmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women, the choice of whether or not to begin therapy requires knowledge of the risks and benefits of estrogen and/or progestin replacement. The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy.
18488874	0	2	HT	Disease	MESH:D006973
18488874	24	55	estradiol/norethindrone acetate	Chemical	-
18488874	324	329	woman	Species	9606
18488874	350	355	women	Species	9606
18488874	588	619	estradiol/norethindrone acetate	Chemical	-

